Denmark-based medical foundation Novo has used its quasi-corporate venturing unit to co-lead the £4m ($6.5m) series B round for Vantia Therapeutics, a UK-based drugs company.

Venture capital (VC) firm SV Life Sciences also co-led the B round, which included VC peer MVM Life Science Partners and all existing investors in Vantia.

MVM, SV and Novo had spun Vantia out from Ferring Pharmaceuticals with up to £19m in March 2008.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?